Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oncolytics Biotech Inc. - Common Shares (NQ:ONCY)

1.070 +0.030 (+2.88%)
Streaming Delayed Price Updated: 9:49 AM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 92,674
Open 1.060
Bid (Size) 1.070 (500)
Ask (Size) 1.080 (500)
Prev. Close 1.040
Today's Range 1.060 - 1.090
52wk Range 0.3258 - 1.510
Shares Outstanding 46,166,980
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy
From Oncolytics Biotech® Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga

Performance

YTD
+15.1%
+15.1%
1 Month
-9.3%
-9.3%
3 Month
+5.9%
+5.9%
6 Month
+140.7%
+140.7%
1 Year
+7.5%
+7.5%

More News

Read More
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Earnings Scheduled For August 8, 2025 ↗
Via Benzinga
News headline image
What to Expect from Oncolytics Biotech's Earnings ↗
Via Benzinga
News headline image
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
Via FinancialNewsMedia
News headline image
Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies
Via FinancialNewsMedia
News headline image
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
From FN Media Group LLC
Via GlobeNewswire
News headline image
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough
Via FinancialNewsMedia
News headline image
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
Via FinancialNewsMedia
News headline image
Cancer Rates Are Surging in Young Adults — Here’s Where the Smart Money Is Going
Via FinancialNewsMedia
News headline image
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs
Via FinancialNewsMedia
News headline image
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
From FN Media Group LLC
Via GlobeNewswire
News headline image
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Earnings Scheduled For May 14, 2025 ↗
Via Benzinga
News headline image
A Look at Oncolytics Biotech's Upcoming Earnings Report ↗
Via Benzinga
News headline image
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Earnings Scheduled For March 7, 2025 ↗
Via Benzinga
News headline image
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer
Via FinancialNewsMedia
News headline image
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium
Via FinancialNewsMedia
News headline image
Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data
Via FinancialNewsMedia
News headline image
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
From FN Media Group LLC
Via GlobeNewswire
News headline image
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
Via FinancialNewsMedia

Frequently Asked Questions

Is Oncolytics Biotech Inc. - Common Shares publicly traded?
Yes, Oncolytics Biotech Inc. - Common Shares is publicly traded.
What exchange does Oncolytics Biotech Inc. - Common Shares trade on?
Oncolytics Biotech Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Oncolytics Biotech Inc. - Common Shares?
The ticker symbol for Oncolytics Biotech Inc. - Common Shares is ONCY on the Nasdaq Stock Market
What is the current price of Oncolytics Biotech Inc. - Common Shares?
The current price of Oncolytics Biotech Inc. - Common Shares is 1.070
When was Oncolytics Biotech Inc. - Common Shares last traded?
The last trade of Oncolytics Biotech Inc. - Common Shares was at 11/17/25 09:49 AM ET
What is the market capitalization of Oncolytics Biotech Inc. - Common Shares?
The market capitalization of Oncolytics Biotech Inc. - Common Shares is 49.40M
How many shares of Oncolytics Biotech Inc. - Common Shares are outstanding?
Oncolytics Biotech Inc. - Common Shares has 49M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.